211 related articles for article (PubMed ID: 30746017)
21. Safety and efficacy of omadacycline by BMI categories and diabetes history in two Phase III randomized studies of patients with acute bacterial skin and skin structure infections.
Pai MP; Wilcox MH; Chitra S; McGovern PC
J Antimicrob Chemother; 2021 Apr; 76(5):1315-1322. PubMed ID: 33458763
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials.
Lodise TP; Redell M; Armstrong SO; Sulham KA; Corey GR
Open Forum Infect Dis; 2017; 4(1):ofw274. PubMed ID: 28480266
[TBL] [Abstract][Full Text] [Related]
23. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.
Huband MD; Pfaller MA; Shortridge D; Flamm RK
J Glob Antimicrob Resist; 2019 Dec; 19():56-63. PubMed ID: 30825698
[TBL] [Abstract][Full Text] [Related]
24. An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline.
Kovacs SJ; Ting L; Praestgaard J; Sunkara G; Sun H; Stein DS; Tanaka SK; Villano S
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32839218
[TBL] [Abstract][Full Text] [Related]
25. Potential for Cost Saving with Iclaprim Owing to Avoidance of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections.
Patel N; Huang D; Lodise T
Clin Drug Investig; 2018 Oct; 38(10):935-943. PubMed ID: 30105549
[TBL] [Abstract][Full Text] [Related]
26. Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for
Lodise T; Rodriguez M; Chitra S; Wright K; Patel N
Antibiotics (Basel); 2021 Oct; 10(10):. PubMed ID: 34680776
[TBL] [Abstract][Full Text] [Related]
27. Outpatient care concept and potential inpatient cost savings associated with the administration of dalbavancin - A real-world data and retrospective cost analysis.
Baltin CT; Wulf C; Rongisch R; Lehmann C; Wingen-Heimann S; Eisenmenger N; Bonn J; Fabri M; von Stebut E; Cornely OA; Kron F
J Infect Public Health; 2023 Jun; 16(6):955-963. PubMed ID: 37099955
[TBL] [Abstract][Full Text] [Related]
28. Return of the tetracyclines: omadacycline, a novel aminomethylcycline antimicrobial.
Cho JC; Childs-Kean LM; Zmarlicka MT; Crotty MP
Drugs Today (Barc); 2018 Mar; 54(3):209-217. PubMed ID: 29771255
[TBL] [Abstract][Full Text] [Related]
29. Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin.
Stephens JM; Gao X; Patel DA; Verheggen BG; Shelbaya A; Haider S
Clinicoecon Outcomes Res; 2013; 5():447-57. PubMed ID: 24068869
[TBL] [Abstract][Full Text] [Related]
30. A Review of Omadacycline for Potential Utility in the Military Health System for the Treatment of Wound Infections.
Zurawski DV; Serio AW; Black C; Pybus B; Akers KS; Deck DH; Johnson S; Chattagul S; Noble SM; Raynor M; Lanteri CA
Mil Med; 2024 May; 189(5-6):e1353-e1361. PubMed ID: 37963013
[TBL] [Abstract][Full Text] [Related]
31. Omadacycline: A Novel Tetracycline Derivative With Oral and Intravenous Formulations.
Watkins RR; Deresinski S
Clin Infect Dis; 2019 Aug; 69(5):890-896. PubMed ID: 30893428
[TBL] [Abstract][Full Text] [Related]
32. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections.
Villano S; Steenbergen J; Loh E
Future Microbiol; 2016 Oct; 11():1421-1434. PubMed ID: 27539442
[TBL] [Abstract][Full Text] [Related]
33. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
[TBL] [Abstract][Full Text] [Related]
34. Modeling economic implications of alternative treatment strategies for acute bacterial skin and skin structure infections.
Revankar N; Ward AJ; Pelligra CG; Kongnakorn T; Fan W; LaPensee KT
J Med Econ; 2014 Oct; 17(10):730-40. PubMed ID: 25019580
[TBL] [Abstract][Full Text] [Related]
35. Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline Versus Vancomycin in Healthy Volunteers.
Jo J; Hu C; Begum K; Wang W; Le TM; Agyapong S; Hanson BM; Ayele H; Lancaster C; Jahangir Alam M; Gonzales-Luna AJ; Garey KW
J Infect Dis; 2024 Jan; 229(1):273-281. PubMed ID: 38051631
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline.
Macone AB; Caruso BK; Leahy RG; Donatelli J; Weir S; Draper MP; Tanaka SK; Levy SB
Antimicrob Agents Chemother; 2014; 58(2):1127-35. PubMed ID: 24295985
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function.
Berg JK; Tzanis E; Garrity-Ryan L; Bai S; Chitra S; Manley A; Villano S
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158281
[TBL] [Abstract][Full Text] [Related]
38. Omadacycline in Skin Infections and Pneumonia: A Review of the Evidence.
Vacalis S; Brunton S; Gindi J
J Fam Pract; 2022 Jun; 71(5 Suppl):S10-S21. PubMed ID: 35776862
[TBL] [Abstract][Full Text] [Related]
39. A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections.
Noel GJ; Draper MP; Hait H; Tanaka SK; Arbeit RD
Antimicrob Agents Chemother; 2012 Nov; 56(11):5650-4. PubMed ID: 22908151
[TBL] [Abstract][Full Text] [Related]
40. Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study.
Anastasio PJ; Wolthoff P; Galli A; Fan W
Infect Dis Ther; 2017 Mar; 6(1):115-128. PubMed ID: 28078655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
